Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

Abstract:

:Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 consecutive, not previously transplanted patients who were enrolled in phase II studies of imatinib. Of 30 patients eligible for SCT, 22 (73%) were actually transplanted. Ten patients were in complete hematologic remission (CHR) (n = 5) or had a complete marrow response (CMR) (n = 5) at the time of SCT, 12 patients had again relapsed or were refractory. After SCT, 18 patients were in complete remission, one patient was refractory, three patients died prior to response assessment. Seven patients (32%) are in ongoing complete remission with a median follow-up of 9.4 (range 1.7-23.8) months. Seven patients (32%) relapsed a median of 5.2 months after SCT. Transplant-related mortality (TRM) was 36%. Probability of disease-free survival (DFS) is 25.5 +/- 9.8% overall and 51.4 +/- 17.7% when SCT was performed in CHR or CMR, compared with 8.3 +/- 8% for SCT during overt leukemia (P = 0.06). In conclusion, imatinib is a well-tolerated salvage therapy prior to allogeneic SCT in patients with Ph+ALL, but requires that SCT be performed within a few weeks of starting treatment to avoid resistance. Disease status at time of transplantation is an important determinant of DFS and TRM.

journal_name

Leukemia

journal_title

Leukemia

authors

Wassmann B,Pfeifer H,Scheuring U,Klein SA,Gökbuget N,Binckebanck A,Martin H,Gschaidmeier H,Hoelzer D,Ottmann OG

doi

10.1038/sj.leu.2402770

subject

Has Abstract

pub_date

2002-12-01 00:00:00

pages

2358-65

issue

12

eissn

0887-6924

issn

1476-5551

journal_volume

16

pub_type

临床试验,杂志文章

相关文献

LEUKEMIA文献大全
  • A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

    abstract::Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for counseling, choice of therapy and the design and interpretation of clinical investigation. Indeed, as in acute le...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404516

    authors: Stewart AK,Bergsagel PL,Greipp PR,Dispenzieri A,Gertz MA,Hayman SR,Kumar S,Lacy MQ,Lust JA,Russell SJ,Witzig TE,Zeldenrust SR,Dingli D,Reeder CB,Roy V,Kyle RA,Rajkumar SV,Fonseca R

    更新日期:2007-03-01 00:00:00

  • Growth and differentiation of a murine interleukin-3-producing myelomonocytic leukemia cell line in a protein-free chemically defined medium.

    abstract::We established the continuous growth of WEHI-3B D+ cells in protein-free chemically defined F-12 medium by stepwise decreases in the concentration of fetal calf serum. This cell line, designated as WEHI-3B-Y1, has now been propagated in protein-free F-12 medium for 3 years. The population-doubling time of the cells in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kajigaya Y,Ikuta K,Sasaki H,Matsuyama S

    更新日期:1990-10-01 00:00:00

  • Microsatellite instability in childhood T cell acute lymphoblastic leukemia.

    abstract::Acute lymphoblastic leukemia (ALL) is the most frequent cancer encountered in children. Little is known about the molecular pathology of childhood T cell ALL. Oncogenesis is a multistep process that involves alterations in proto-oncogenes and tumor suppressor genes. Recently, a mutator phenotype detectable by microsat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400650

    authors: Baccichet A,Benachenhou N,Couture F,Leclerc JM,Sinnett D

    更新日期:1997-06-01 00:00:00

  • Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.

    abstract::The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

    更新日期:1992-01-01 00:00:00

  • Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.

    abstract::The monitoring of chimerism by PCR has become a routine diagnostic approach in patients after allogeneic bone marrow or peripheral blood stem cell transplantation. Nevertheless, a temporal correlation between molecular and hematologic assessment of engraftment has not been clearly established. To address this issue, a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dubovsky J,Daxberger H,Fritsch G,Printz D,Peters C,Matthes S,Gadner H,Lion T,Muller-Bérat N

    更新日期:1999-12-01 00:00:00

  • Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

    abstract::Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predict treatment failur...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-019-0512-y

    authors: Branford S,Kim DDH,Apperley JF,Eide CA,Mustjoki S,Ong ST,Nteliopoulos G,Ernst T,Chuah C,Gambacorti-Passerini C,Mauro MJ,Druker BJ,Kim DW,Mahon FX,Cortes J,Radich JP,Hochhaus A,Hughes TP,International CML Foundation Ge

    更新日期:2019-08-01 00:00:00

  • Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

    abstract::Two proteins that have been correlated with the occurrence of multidrug resistance in acute myeloid leukemia (AML) are P-glycoprotein (Pgp) and the major vault protein (Mvp/LRP). With the purpose of further quantifying the potential contributions of Pgp-mediated drug efflux and Mvp/LRP to drug resistance in AML we hav...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401331

    authors: Broxterman HJ,Sonneveld P,Pieters R,Lankelma J,Eekman CA,Loonen AH,Schoester M,Ossenkoppele GJ,Löwenberg B,Pinedo HM,Schuurhuis GJ

    更新日期:1999-02-01 00:00:00

  • KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

    abstract::To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.330

    authors: Clipson A,Wang M,de Leval L,Ashton-Key M,Wotherspoon A,Vassiliou G,Bolli N,Grove C,Moody S,Escudero-Ibarz L,Gundem G,Brugger K,Xue X,Mi E,Bench A,Scott M,Liu H,Follows G,Robles EF,Martinez-Climent JA,Oscier D,Wa

    更新日期:2015-05-01 00:00:00

  • Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes.

    abstract::Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400694

    authors: Terpstra W,Leenen PJ,van den Bos C,Prins A,Loenen WA,Verstegen MM,van Wyngaardt S,van Rooijen N,Wognum AW,Wagemaker G,Wielenga JJ,Löwenberg B

    更新日期:1997-07-01 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract::It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402013

    authors: Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期:2001-02-01 00:00:00

  • OCT1 and imatinib transport in CML: is it clinically relevant?

    abstract::Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2015.170

    authors: Watkins DB,Hughes TP,White DL

    更新日期:2015-10-01 00:00:00

  • Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.

    abstract::We have developed a method to quantify topoisomerase (topo) II activities in partially purified nuclear extracts from human leukemia cells. By virtue of their different pH optima in the reaction buffer, two different topo II activities were found with activity optima at pH 7.9 and at pH 8.9 under high stringency condi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gieseler F,Glasmacher A,Kämpfe D,Wandt H,Nuessler V,Valsamas S,Kunze J,Wilms K

    更新日期:1996-07-01 00:00:00

  • Functional role of PECAM-1/CD31 molecule expressed on human cord blood progenitors.

    abstract::CD31/PECAM-1 (platelet endothelial cell adhesion molecule-1) is a 130 kDa integral membrane protein of the immunoglobulin gene superfamily with the distinctive feature of being expressed on several cell types associated with the vascular compartment. In the present study we report a novel, unique CD31 mAb termed IP28A...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: El-Marsafy S,Carosella ED,Agrawal SG,Gluckman E,Mansur IG,Elhabazi A,Boumsell L,Bensussan A

    更新日期:1996-08-01 00:00:00

  • SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

    abstract::Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.256

    authors: Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

    更新日期:2014-04-01 00:00:00

  • Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.

    abstract::The chimeric fusion oncogene early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB) is a recurrent lesion observed in Philadelphia-like B-acute lymphoblastic leukemia (B-ALL) and is associated with particularly poor prognosis. While it is understood that this fusion activates tyrosine kinase sig...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.166

    authors: Welsh SJ,Churchman ML,Togni M,Mullighan CG,Hagman J

    更新日期:2018-01-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Monoclonal antibodies specific for P-glycoprotein.

    abstract::Multidrug resistance (MDR) is one of the major obstacles to successful cancer chemotherapy. Since P-glycoprotein (P-gp) encoded by the MDR-1 gene plays a key role in MDR, many P-gp-specific monoclonal antibodies (MAbs) have been generated for characterization and analysis of P-gp. Among those antibodies, MRK16 has bee...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400658

    authors: Okochi E,Iwahashi T,Tsuruo T

    更新日期:1997-07-01 00:00:00

  • Molecular remission as a therapeutic objective in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemogenesis, this genetic aberration serves as a disease-specific biomarker for rapid diagnosis and monitoring o...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0219-5

    authors: Cicconi L,Fenaux P,Kantarjian H,Tallman M,Sanz MA,Lo-Coco F

    更新日期:2018-08-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Integrin distribution and cytoskeleton organization in normal and malignant monocytes.

    abstract::In this work we have mapped by double-label immunofluorescence the cellular distribution of integrins and their relationship with cytoskeletal proteins in normal and malignant monocytes. In normal monocytes, CD18 and CD11c are concentrated at specific adhesion sites, named podosomes, together with actin, vinculin, and...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gaidano G,Bergui L,Schena M,Gaboli M,Cremona O,Marchisio PC,Caligaris-Cappio F

    更新日期:1990-10-01 00:00:00

  • Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

    abstract::Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present in different malignancies. This meeting report summarizes some of the recent advances in leukemia treatment. Based on the discoveries of cellular oncogenes, chromosomal translocations, monocl...

    journal_title:Leukemia

    pub_type:

    doi:10.1038/sj.leu.2403156

    authors: Larson RA,Daley GQ,Schiffer CA,Porcu P,Pui CH,Marie JP,Steelman LS,Bertrand FE,McCubrey JA

    更新日期:2003-12-01 00:00:00

  • Molecular investigation of the cytokines produced by normal and malignant B lymphocytes.

    abstract::Different normal and malignant human B-cell populations were studied with a twofold aim: to define which cytokines are produced in vivo, and to assess the relationship between cytokine production and kinetic state. To analyse normal B-cells representative of different stages of activation and proliferation in vivo, we...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Schena M,Gaidano G,Gottardi D,Malavasi F,Larsson LG,Nilsson K,Caligaris-Cappio F

    更新日期:1992-02-01 00:00:00

  • Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.

    abstract::The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in mast cell growth and differentiation. In a human mast cell leukemia cell line (HMC-1), KitR was found to be constitutively phosphorylated on tyrosine, activated and associated with phosphatidylinositol 3-kinase (P13K) i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kanakura Y,Furitsu T,Tsujimura T,Butterfield JH,Ashman LK,Ikeda H,Kitayama H,Kanayama Y,Matsuzawa Y,Kitamura Y

    更新日期:1994-04-01 00:00:00

  • Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.

    abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402031

    authors: Nakamura N,Kuze T,Hashimoto Y,Hara Y,Hoshi S,Sasaki Y,Shirakawa A,Sato M,Abe M

    更新日期:2001-03-01 00:00:00

  • NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

    abstract::Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/leu.2010.205

    authors: Clappier E,Collette S,Grardel N,Girard S,Suarez L,Brunie G,Kaltenbach S,Yakouben K,Mazingue F,Robert A,Boutard P,Plantaz D,Rohrlich P,van Vlierberghe P,Preudhomme C,Otten J,Speleman F,Dastugue N,Suciu S,Benoit Y,B

    更新日期:2010-12-01 00:00:00

  • A revisionist history of adult marrow stem cell biology or 'they forgot about the discard'.

    abstract::The adult marrow hematopoietic stem cell biology has largely been based on studies of highly purified stem cells. This is unfortunate because during the stem cell purification the great bulk of stem cells are discarded. These cells are actively proliferating. The final purified stem cell is dormant and not representat...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2017.155

    authors: Quesenberry P,Goldberg L

    更新日期:2017-08-01 00:00:00

  • Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.

    abstract::Bryostatin 1 is a macrocyclic lactone activator of protein kinase C which has displayed promising antileukemic potential in pre-clinical studies. We have assessed the effect of bryostatin 1 on the in vitro clonogenic response of leukemic myeloblasts obtained from 12 patients with acute non-lymphocytic leukemia to reco...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Grant S,Pettit GR,Howe C,McCrady C

    更新日期:1991-05-01 00:00:00

  • Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.

    abstract::The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403943

    authors: Meier M,den Boer ML,Hall AG,Irving JA,Passier M,Minto L,van Wering ER,Janka-Schaub GE,Pieters R

    更新日期:2005-11-01 00:00:00

  • RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

    abstract::Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. A...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0403-2

    authors: Zhou N,Gutierrez-Uzquiza A,Zheng XY,Chang R,Vogl DT,Garfall AL,Bernabei L,Saraf A,Florens L,Washburn MP,Illendula A,Bushweller JH,Busino L

    更新日期:2019-08-01 00:00:00

  • Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature.

    abstract::Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400678

    authors: Rockman SP

    更新日期:1997-06-01 00:00:00